| 1 |
34276365 | Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. | 2021 |
1 |
| 2 |
34659899 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | 2021 |
2 |
| 3 |
25712455 | A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. | 2015 Jun |
1 |
| 4 |
25803811 | Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1. | 2015 |
1 |
| 5 |
25053825 | BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. | 2014 Oct |
1 |
| 6 |
22781593 | Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. | 2013 Jan |
1 |